[Antibiotherapy as first choice in infectious meningitis]

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Bacterial meningitis treatment selection hinges on pathogen epidemiology, antibiotic resistance, and pharmacokinetic properties.
• Key pathogens include Haemophilus influenzae (Hi), Neisseria meningitidis (Nm), and Streptococcus pneumoniae (Sp), accounting for over 95% of community-acquired cases.
• Increasing antibiotic resistance, especially in Streptococcus pneumoniae, complicates treatment strategies.

Framework:

• Antibiotic efficacy in meningitis depends on achieving concentrations significantly higher than the Minimum Bactericidal Concentration (MBC) within the cerebrospinal fluid (CSF).
• Cerebrospinal fluid (CSF) presents a challenging environment for antibiotic activity.
• Clinical trials and animal models are crucial for understanding meningitis pathophysiology and evaluating treatment effectiveness.

Implementation:

• Third-generation cephalosporins (cefotaxime, ceftriaxone) are recommended for Haemophilus influenzae (Hi), Neisseria meningitidis (Nm), and penicillin-susceptible Streptococcus pneumoniae (Sp).
• Penicillin-resistant Streptococcus pneumoniae (Sp) strains pose a therapeutic challenge, often failing to reach adequate antibiotic concentrations in CSF.
• Management of resistant strains may involve increased cephalosporin dosages, alternative agents like Vancomycin or Imipenem, or combination therapy with agents such as Rifamycin or Fosfomycin.

Implications:

• Optimizing antibiotic selection is critical for improving patient outcomes in bacterial meningitis.
• Addressing antibiotic resistance in Streptococcus pneumoniae is a priority for effective meningitis treatment.
• Further research into novel therapeutic strategies and drug combinations is warranted for challenging meningitis cases.